TORONTO--(BUSINESS WIRE)--Merz Pharma Canada, Ltd., affiliate of the global Merz Pharma Group, today announced that it has an exclusive arrangement with Anteis S.A. (Switzerland) which grants Merz sole rights for the marketing and distribution of the full line of Anteis products in Canada, including the Esthélis™, Fortélis™, Modélis™ and Mesolis™ brands and the Anteis Injection System.
“This expansion of our presence in the Canadian aesthetics market is a significant milestone, not only for our North America organization, but also for Merz’s development as a global aesthetics company,” said Bill Humphries, President and Chief Executive Officer. “We look forward to further collaboration with Anteis in the near future, as we work to bring their full range of aesthetic injectables to Merz affiliates around the world.“
A strong global player in the area of injectable medical devices, Anteis was acquired by the Merz Pharma Group in November 2013 as part of Merz’s strategy to further establish its leadership in aesthetics. Anteis has developed several highly innovative and highly differentiated products in the field of aesthetics, as well as a proprietary injection system for its dermal fillers.
“We are pleased to assume responsibility for the marketing of the full range of Anteis products,” said Bob Bennett, President and General Manager of Merz Pharma Canada, Ltd. “This agreement establishes Merz Pharma Canada as one of the leading distributors of injectable aesthetic products within the Canadian market, as well as the first Merz affiliate to offer the entire line of injectable dermal fillers manufactured by Anteis.“
The dermal fillers Esthélis Basic and Esthélis Soft were first granted license by Health Canada in May 2006; all current formulations with integrated lidocaine were licensed by Health Canada in July 2013. Anteis products were previously distributed in Canada by MD Medical.
About Merz North America
Merz North America is a specialty healthcare company that develops and commercializes innovative, high-quality treatment solutions in aesthetics, dermatology and neurosciences in the U.S. and Canada. Our ambition is to become the most admired, trusted and innovative aesthetics and neurotoxin company. By developing products that improve patients’ health and help them to live better, feel better and look better, we will continue to make significant contributions to the well-being of individuals around the world.
For more information about Merz Pharma Canada, Ltd. or their products, please visit www.merzcanada.com. For information regarding Merz products and operations in the United States, please visit www.merzusa.com.
ESTHELIS, FORTELIS, MESOLIS AND MODELIS are trademarks of Anteis S.A.